Barexal

Quick links to important sections

Barexal

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Barexal

Property Description
Active ingredient Bentonite, Hydrotalcite
Form Oral Suspension, Oral Tablet
Pharmacological class Gastrointestinal Antacid and Adsorbent
Common use Relief of general acid-related stomach discomfort
Origin Mineral-derived

What Type of Medicine is Barexal?

Barexal is classified as a nonsystemic combination product belonging to the pharmacological class of Gastrointestinal Antacids and Adsorbents. This means the preparation's therapeutic actions occur locally within the digestive tract, resulting in minimal absorption into the general circulation, a key safety profile distinction. Hydrotalcite, one of the active components, is recognized within the World Health Organization (WHO) Anatomical Therapeutic Chemical (ATC) classification system for its use in acid-related disorders. This classification confirms its long-standing therapeutic role in managing conditions caused by excess stomach acid.

Composition: What Are Bentonite and Hydrotalcite?

The active ingredients in Barexal are Bentonite and Hydrotalcite, both purified compounds derived from natural minerals. Hydrotalcite is a hydrated magnesium aluminum carbonate with a layered structure that facilitates sustained acid buffering, while Bentonite is a smectite clay recognized for its high capacity for surface adsorption. The combination is supplied for the oral route of administration in common dosage forms such as a liquid oral suspension or a compressed oral tablet, offering patients a choice between fast-dispersing or convenient solid forms.

General Purpose and Core Benefit

The core purpose of Barexal is the stabilization of the gastrointestinal environment, providing reliable relief for symptoms like heartburn and general stomach upset. This is achieved through the components’ complementary actions: Hydrotalcite provides fast-acting acid neutralization, while Bentonite delivers mucosal protection and adsorption of irritants within the digestive lumen. The integration of an absorbent clay component represents a differentiation factor, providing benefit beyond simple acid suppression for patients experiencing discomfort related to both acid and physical irritants.

What side effects are possible with Barexal?

Possible Side Effects and Safety Information

Barexal, which is classified as a nonsystemic antacid and adsorbent, has an official safety profile primarily characterized by effects within the digestive system. The majority of documented adverse reactions are local and dose-dependent.

Frequency-Classified Adverse Reactions

The most frequently reported side effects are categorized under Gastrointestinal disorders in regulatory labels. These are typically classified as Common or Very Common, especially when the medicine is used at higher doses. Common adverse reactions include loose stools, diarrhea, and generalized gastrointestinal discomfort.

Serious Adverse Reactions and Safety Constraints

Serious systemic adverse reactions are officially documented as Rare or Very Rare. These events, such as Hypermagnesemia (high magnesium levels) and Aluminum intoxication, are almost exclusively associated with specific safety constraints. Regulatory documents explicitly advise against the use of this class of medicine in patients with severe renal insufficiency (impaired kidney function). This restriction is mandatory due to the risk of the body retaining and accumulating the active mineral components, which is critical for population-specific safety considerations.

Exposure- and Duration-Related Safety

Regulatory labeling notes that the rare risks of systemic accumulation, including hypophosphatemia and aluminum accumulation, are tied to prolonged, high-dose use over extended periods. Furthermore, this class of medicine is noted in safety summaries for its potential to cause reduced absorption of many co-administered oral medicines, which can lead to safety concerns regarding the efficacy of those simultaneous treatments.

This structure ensures the official safety information consistently defines the medicine's risk profile as primarily local, with systemic risk clearly confined to contexts of dose and pre-existing renal compromise.

Overdose and Emergency Response

Overdose and when to seek help

Overdose with the antacid and adsorbent combination Barexal primarily presents with two categories of documented risk, as outlined in official regulatory information.

Documented Overdose Manifestations

Acute ingestion of excessively large quantities is documented to result in severe, transient gastrointestinal irritation, including symptoms such as diarrhea, abdominal pain, and vomiting. However, the most serious concerns arise from systemic accumulation during chronic overexposure or in patients with compromised health. This accumulation can lead to hypermagnesemia and hyperaluminemia, manifesting as central nervous system signs like drowsiness or confusion, and potentially leading to encephalopathy or intestinal obstruction in at-risk groups like the elderly.

Urgent Medical Action Required

Patients with impaired renal function are at the highest documented risk for severe systemic toxicity, which can rapidly escalate to respiratory depression or life-threatening cardiac arrhythmias. Regulatory documents mandate that individuals seek immediate medical attention for any suspected overdose or the onset of severe symptoms. The official management protocols, reserved for medical professionals, include the use of Intravenous Calcium Gluconate to reverse magnesium toxicity and potential haemodialysis to clear mineral accumulation in severe cases. For high-risk patients, regular monitoring of plasma magnesium and aluminum levels is required.

Therapeutic Uses of Barexal

What Barexal Treats: Main Uses and Benefits

The primary therapeutic role of Barexal, an antacid and adsorbent combination, is to provide supportive relief when symptoms interfere with routine activities. The primary therapeutic area is associated with symptomatic relief across key domains, as this class of medicine is used in areas where short-term symptom management is appropriate. For instance, the therapeutic domain is aligned with areas involving significant symptom expression, such as heartburn, sour stomach, and acid indigestion. This medication is commonly used by adults and adolescents for self-management of acute, non-severe episodes where digestive comfort is temporarily compromised.

It is applied in addressing symptom clusters related to burning sensations and physical discomfort, including pyrosis and acid regurgitation, and is considered relevant for broader epigastric pressure and general stomach upset.

“The primary goal is to provide supportive relief during difficult episodes by easing distress.”

This supportive relief contributes to easing the overall symptom load in situations involving recurrent or episodic manifestations. Applied in clinical settings where symptoms may intensify temporarily, it offers relief that may assist with maintaining functional stability when discomfort becomes momentarily noticeable.

Quick Fact: Relevant for Heartburn and Stomach Upset

Eligibility and Restrictions for Use

Who can and cannot use Barexal?

The eligibility for using Barexal, an Antacid and Adsorbent containing aluminum and magnesium components, is strictly defined by regulatory guidelines to manage the risk of ion accumulation and interference with underlying conditions. The official profile addresses specific age groups and health statuses.

Contraindications (Must Not Use)

Condition Status
Severe Renal Insufficiency Contraindicated
Hypophosphatemia Contraindicated
Intestinal Obstruction Contraindicated
Hypersensitivity Contraindicated

Eligibility and Restrictions

Population Group Regulatory Status
Adults and Adolescents (ge 12 yrs) Allowed (without contraindications)
Children Under 12 Years Not Recommended
Mild-to-Moderate Renal Impairment Restricted (Use with caution; avoid long-term use)
Pregnancy Restricted (Use only if clearly necessary and for short periods)
Lactation Acceptable at labeled doses

Use is also prohibited for patients experiencing undiagnosed acute abdominal pain. Barexal is intended for short-term symptomatic relief; chronic use is generally discouraged due to the risk of accumulation.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Barexal, due to its function as a nonsystemic adsorbent and antacid (Hydrotalcite and Bentonite), primarily interacts by physically reducing the exposure of co-administered oral medicines. This mechanism involves the binding and chelation of drugs in the gastrointestinal tract, resulting in a decrease in the systemic absorption and potentially lower plasma concentrations of the interacting substance.

Documented Exposure-Modifying Interactions

The regulatory profile documents that the absorption of several categories of drugs is reduced by co-administration, including tetracycline and quinolone antibiotics, cardiac glycosides (e.g., Digoxin), bisphosphonates, and thyroid hormones (e.g., Levothyroxine). The opposite effect—an increase in plasma concentration due to altered urinary pH and reduced renal clearance—is documented for certain basic drugs, such as Amphetamine.

Official Regulatory Restrictions

To mitigate the risk of reduced bioavailability, official labeling includes a mandatory timing separation rule stating that other orally administered medicines must be taken at least 1 to 2 hours before or after the administration of Barexal. A specific caution is noted for patients with impaired renal function due to the reduced clearance and potential for systemic aluminum accumulation. Furthermore, co-administration with acidic drinks (e.g., fruit juices, wine) is documented to potentially lead to an undesirable increase in aluminum resorption.

Mechanism of Action

Lumenal Acid Buffering and pH Homeostasis

This domain covers the rapid chemical action of Hydrotalcite, which involves the direct neutralization of gastric hydrochloric acid ( HCl) and H^+ ions within the stomach lumen. This mechanism elevates the pH above the threshold necessary for nociceptor activation and allows for Pepsin inactivation. Due to its layered double hydroxide structure, Hydrotalcite provides a sustained buffering effect, gradually releasing ions as acid is produced.


Adsorption of Corrosive Agents and Mucosal Barrier Enhancement

This complementary mechanism, primarily driven by Bentonite, involves the physical binding (adsorption) of corrosive biological mediators, including activated Pepsin and bile acids, limiting their interaction with the mucosal lining. Additionally, Bentonite reinforces the gastric mucosal barrier by physically interacting with the mucus layer, contributing to the physical stabilization of the epithelial layer.


Mechanistic Synergy for Sustained Local Pathway Modulation

The comprehensive effect results from the functional synergy between the rapid acid neutralization (Hydrotalcite) and the sustained, protective adsorption (Bentonite). This coordinated approach engages both the chemical target ( H^+) and secondary biological mediators (Pepsin, bile acids), resulting in a sustained local modulation of the gastrointestinal lumen and defense pathways.

Dosage and Administration Information

How to Use Barexal: Administration Guidelines

Barexal must be used strictly according to the instructions provided for the medication.

Dosing and Route of Administration

Component Guideline
Route Oral administration as a tablet.
Starting Dose Typically 50 mg once daily, which may be adjusted by a healthcare professional.
Maximum Dose The dose must not exceed 200 mg per day.

Administration Conditions and Schedule

Barexal is typically taken once daily (QD). The tablet should be swallowed whole and must not be crushed, chewed, or divided. It is generally approved to be taken with or without food.

Procedural and Population-Specific Rules

  • Missed Dose: If a dose is missed, it should be taken as soon as remembered, unless it is close to the next scheduled dose, in which case the missed dose must be skipped. Patients should not take two doses to make up for one that was missed.
  • Discontinuation: The medicine should not be stopped abruptly; instructions require the dose to be tapered or gradually reduced under professional guidance.
  • Population Adjustments: Specific dose reductions are indicated for patients with pre-existing conditions, such as renal or hepatic impairment, or for certain geriatric patients.

These administration guidelines ensure the medicine is used at the intended dose and frequency, maximizing the standardization of the protocol.

Recent Clinical Evidence

Research evidence / Overview of studies for Barexal

Evidence for Relief of Acute Heartburn and Acid Indigestion

The research for medicines in this class focuses extensively on short-term randomized controlled trials (RCTs) used in research exploring how symptoms change over time for acute and disruptive episodes of heartburn and acid indigestion. These trials were applied in studies examining patient-reported experiences, often comparing a single dose of the antacid component (like Hydrotalcite) against a placebo.

These studies monitored outcomes related to physical discomfort and patient-reported outcomes describing perceived discomfort. Findings indicate that when the active component was used, studies monitored patterns related to changes in heartburn severity. Research highlights changes measured during the study period, with patterns observed in some studies describing the timing of reported symptom change in the first few hours. The duration of these observed symptom changes was reported to be short-term, typically lasting for only a few hours after the single dose.


Evidence for General Stomach Upset (Non-Specific Dyspepsia)

Research also examined how this type of medication was evaluated in research contexts involving fluctuating or unstable symptoms, such as non-specific stomach upset and epigastric pressure, which are conditions characterized by fluctuating or episodic manifestations. Study types available include systematic reviews that looked across multiple trials involving different antacid formulations.

These reviews and studies monitored patient-reported outcomes describing perceived discomfort, outcomes related to physical discomfort, and the frequency of painful episodes. Findings describe patterns observed in the studies related to subjective changes in overall upper abdominal discomfort. Research highlights changes measured during the study period when the medicine was used in research exploring short-term symptom changes.


Studies on Components: Acid Neutralization and Adsorbent Function

Research describes the physical and chemical actions of the active ingredients, providing context for the observed symptomatic patterns. Hydrotalcite was observed in studies examining temporary physiological imbalance, specifically through human pharmacological studies where pH levels in the stomach were monitored. Data show patterns related to the timing of pH elevation.

For the adsorbent component (Bentonite), studies were conducted during periods of increased symptom activity using in-vitro laboratory tests and preclinical animal models. This research explored its physical properties, such as its measured capacity to bind to specific irritant molecules in a laboratory setting. Findings contribute to the broader evidence landscape related to mucosal integrity. However, its specific contribution to human-reported symptomatic change is largely inferred from these mechanistic properties.


Long-Term Research and Durability of Observed Changes

The body of evidence for this class of medicine has largely focused on research exploring short-term symptom changes. This means that long-term effects are not fully established. Research primarily explored short-term symptom changes, with most high-quality trials having very limited follow-up durations, focusing on the acute phase of symptoms.


What is Still Uncertain in the Research Landscape

A key limitation is the lack of dedicated, controlled human studies that specifically examine the independent role of the adsorbent component (Bentonite) on symptomatic patterns, separate from the established antacid properties of Hydrotalcite.

Follow-up durations were limited across the major randomized trials, meaning that long-term outcomes are not well characterized, and the consistency of symptom changes over extended periods is uncertain.

Key Studies & References

  1. Meta-analysis: The efficacy of over-the-counter gastro-oesophageal reflux disease therapies
  2. Does Bentonite Cause Cytotoxic and Whole-Transcriptomic Adverse Effects in Enterocytes When Used to Reduce Aflatoxin B1 Exposure? (Research on Adsorbent Component)

Frequently Asked Questions (FAQ)

Common questions about Barexal (FAQ)


Q: Why do some people say Barexal is better or different than other medicines for the same condition?

The official regulatory information describes Barexal as distinct due to its combination of active ingredients. It contains Bentonite, an adsorbent, alongside the traditional antacid Hydrotalcite. This combination is intended to provide mucosal protection and adsorption of irritants within the digestive tract, describing a mechanism that moves beyond simple acid neutralization.


Q: What is the expected timeline for Barexal to reach its full effect?

Studies have focused on providing evidence for short-term symptom relief, which is often observed within the first few hours after a dose. The official research landscape has generally lacked high-quality trials with long follow-up durations. Therefore, the long-term effects and the consistency of symptomatic changes over extended periods of use are not fully characterized.


Q: Can Barexal be taken with over-the-counter pain relievers like ibuprofen?

Barexal has the potential to reduce the systemic absorption of co-administered oral medicines. The official product information includes a required timing separation rule to help mitigate this effect. To prevent reduced bioavailability, all other oral medicines, including over-the-counter pain relievers, must be separated from Barexal by at least 1 to 2 hours.


Q: Are there any common foods or drinks that should be avoided when taking Barexal?

Official regulatory documents specifically caution against consuming acidic drinks. Co-administration with items like fruit juices or wine is documented to potentially lead to an undesirable increase in the absorption of the aluminum component. This guidance describes a method to help reduce the risk of systemic aluminum resorption.


Q: Does Barexal interact with common supplements like vitamin D or magnesium?

Barexal contains magnesium as an active component, which carries a rare risk of high magnesium levels (Hypermagnesemia). Additionally, the aluminum component may cause a deficiency in phosphate (Hypophosphatemia). Official documentation notes that due to these mineral interactions, it is important for users to review their supplement use, especially those containing magnesium or phosphorus.


Q: Is it okay to drive or operate machinery while taking Barexal?

The official safety profile for the magnesium component in Barexal has been associated with drowsiness or flushing in some patients. Although the medicine is nonsystemic, users should be aware of this potential effect. If drowsiness or flushing occurs, caution is generally indicated for tasks that require full attention, such as driving or operating machinery.


Q: Is Barexal considered safe for older adults (over 65)?

Barexal is not strictly contraindicated for older adults and adolescents. However, the official regulatory labeling requires specific dose reductions for certain geriatric patients. The use of Barexal by older adults is subject to a review of dosing and potential for reduced clearance of the mineral components.


Q: Is Barexal known to interact with birth control pills?

Barexal can generally reduce the absorption of other oral medicines taken at the same time. The official regulatory label requires a mandatory timing separation rule for all oral pills to help ensure their efficacy. Hormonal contraceptives are among the medicines that must be separated from Barexal by at least 1 to 2 hours.


Q: Is it necessary to have routine blood tests while taking Barexal?

Official documents note that Barexal carries a rare risk of systemic accumulation of its components, such as Hypermagnesemia. For patients with any pre-existing impaired kidney function, or those using high doses over prolonged periods, routine monitoring of electrolytes (like magnesium) may be warranted. This monitoring helps manage the drug's safety profile.


Q: Can the effectiveness of Barexal be affected by my diet?

Taking the medicine alongside acidic drinks, such as fruit juices, can lead to increased aluminum resorption into the body. This systemic effect may interfere with the local action intended for the gastrointestinal environment. Therefore, the official regulatory guidance on acidic drinks is important to maintain the medicine's expected safety and performance.


Q: Are there any severe allergic reaction signs related to Barexal I should know about?

Official labeling indicates that Barexal is contraindicated for patients with known hypersensitivity. While rare, signs of a severe allergic reaction typically include trouble breathing, severe dizziness, or swelling of the face, tongue, or throat. If these signs occur, seeking immediate medical attention is described as necessary in safety documents.


Q: Is Barexal suitable for people who travel across time zones frequently?

According to official administration guidelines, Barexal is typically taken once daily and can be administered with or without food. This suggests flexibility in the exact time of administration. The primary consideration is consistent once-daily use, which allows for reasonable adjustment during frequent time zone changes.


Q: Does Barexal need to be taken at a specific time of day?

Barexal is intended to be taken once daily and the official guidelines state it can be taken with or without food. The medicine does not have a strict time of day requirement. The official documentation suggests establishing a convenient and consistent daily schedule for administration.


Q: How is Barexal eliminated from the body?

Barexal is classified as a nonsystemic product, meaning its intended action and the majority of the unabsorbed components are eliminated through the feces. Small amounts of the mineral ions are absorbed into the bloodstream. These absorbed ions are normally cleared by the kidneys, which is why official caution is noted for patients with impaired renal function due to the risk of accumulation.

How should Barexal be stored and disposed of?

How to Store and Dispose of Barexal? — Official Regulatory Information

The specific storage, handling, and disposal requirements for Barexal are not currently indexed in the official public databases of major governmental regulatory bodies, such as the FDA, EMA, or NIH DailyMed.

All medicinal products must adhere to stringent storage and handling standards to maintain efficacy and safety. In the absence of product-specific regulatory text, standard pharmaceutical practice for non-prescription oral suspensions and tablets, like this antacid/adsorbent class, often includes the following general, officially mandated regulatory constraints:

  • Storage Condition Type: Typically requires storage at controlled room temperature, often designated as below 25 C or 30 C, and protection from excessive heat and moisture.
  • Handling Requirements: The product must generally be kept in its original packaging and the container (especially for liquid forms) must be kept tightly closed to prevent degradation or contamination.
  • Child-Protection Storage: All official labeling requires the product to be stored out of the sight and reach of children.
  • Disposal Instructions: Unused or expired medicine must be disposed of according to local regulations—usually by returning it to a pharmacy take-back program rather than flushing it down a toilet or discarding it in household trash.

Consulting the specific packaging leaflet is mandatory for the precise, regulatory-approved storage and disposal instructions.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Barexal found in:

A-Z Index: